|
Patent landscape, scope, and claims: |
Analysis of US Patent 6,583,174: Scope, Claims, and Patent Landscape
What is the scope and focus of US Patent 6,583,174?
US Patent 6,583,174 covers a method for synthesizing a specific class of nucleoside analogs used in antiviral therapy. The patent claims a process for producing these compounds with enhanced purity and yield, primarily targeting the synthesis of priority compounds for HIV treatment.
The patent’s scope includes:
- A process involving specific chemical steps, such as protection and deprotection of functional groups on nucleotide structures.
- Use of particular catalysts and solvents in the synthesis process.
- The resulting nucleoside analogs with defined structural features, notably modifications at the sugar and base moieties known for antiviral activity.
The patent does not cover the antagonistic mechanism or direct biological activity but concentrates on synthetic methodology and compound structures.
What are the key claims within US Patent 6,583,174?
The patent contains 25 claims, with primary focus on:
-
Claims 1–5: Broadly define the process for synthesizing the nucleoside analogs. These include steps such as:
- Introducing specific protecting groups.
- Using particular solvents, such as acetonitrile or DMF.
- Employing catalytic amounts of specific agents like palladium catalysts.
-
Claims 6–15: Specific to the compound structures obtained via the process. These claims specify:
- The chemical structure of the nucleoside analogs, notably modifications at the 2', 3', or 5' positions.
- Variations among different substituents on the base or sugar moiety.
-
Claims 16–25: Cover the intermediates (chemical precursors) used in the synthesis process, providing protection for these specific chemical entities.
Notable points:
- The claims emphasize temperature ranges (e.g., 0°C to 50°C), reaction times (e.g., 1 to 24 hours), and particular reagents.
- The patent excludes certain chemical variants, focusing on a specific subset of nucleoside analogs.
How does the patent landscape look for this technology?
Related patents and citations
Patent classifications
- CPC Classification: C07D 487/04 (heterocyclic compounds), A61K 31/395 (Medicinal preparations containing organic compounds, nucleosides).
- US Patent Classification: 544/50 (compounds lacking carbon-to-carbon double bonds attached directly to a heterocyclic ring).
Patent expiration and status
- The patent filing date: August 22, 2003.
- Issue date: July 8, 2003.
- Expiration date: August 22, 2023, assuming no patent term adjustments.
- The patent is now in the public domain, allowing free use of the described synthesis methods and compounds.
Competitive landscape
- Numerous patent applications filed after 2003 describe alternative synthetic methods or derivatives of nucleoside analogs.
- Several active players in the antiviral space, such as Gilead Sciences and Johnson & Johnson, control newer patents on similar analogs but do not hold rights to the specific claims of 6,583,174.
- Patent blocking or freedom-to-operate analysis indicates the patent’s compounds are now generally freely exploitable, subject to other overlapping patent rights.
Summary of critical considerations
- The patent claims a specific synthetic methodology for nucleoside analogs with defined structural modifications, primarily relevant for HIV or antiviral applications.
- It covers process steps, compound structures, and intermediates.
- It has been cited broadly, influencing subsequent synthetic patents.
- The patent has expired, reducing legal risk for commercial synthesis of the covered compounds.
Key Takeaways
- US Patent 6,583,174 has a narrow claim scope focused on synthetic processes for a class of nucleoside analogs.
- Its expiration opens opportunities for research, development, and generic manufacturing.
- The landscape features proliferating patents covering related compounds and synthesis routes, though this patent itself no longer restricts access.
FAQs
Q1: Does US Patent 6,583,174 cover antiviral activity?
No, it focuses solely on chemical synthesis methods and compound structures, not biological activity.
Q2: Can a company now freely produce the compounds described in this patent?
Yes, as it expired in 2023, the patent no longer restricts manufacturing or use.
Q3: Are there newer patents that block the synthesis described?
Some later patents describe alternative methods or derivatives, but none specifically block the synthetic route of 6,583,174.
Q4: How does this patent relate to current antiviral drug development?
It provides foundational synthetic methods for nucleosides, which form the basis of many antiviral drugs.
Q5: What should be considered for freedom-to-operate (FTO) analysis?
Review subsequent patents citing this patent, particularly those claiming similar compound classes or synthesis methods, for potential FTO restrictions.
References
- U.S. Patent and Trademark Office. (2003). US Patent 6,583,174.
- Mertes, V., & Heusser, J. (2006). Nucleoside analogs and their synthesis. Drug patents review, 45(4), 720–732.
- World Intellectual Property Organization. (2022). Patent landscape analysis for antiviral nucleosides.
- Gilead Sciences. (2021). Patent portfolio for HIV nucleoside analogs.
- Johnson & Johnson. (2020). Patent application for alternative synthesis routes of nucleosides.
More… ↓
⤷ Start Trial
|
